loading
Precedente Chiudi:
$12.73
Aprire:
$12.81
Volume 24 ore:
28,362
Relative Volume:
0.07
Capitalizzazione di mercato:
$766.15M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-4.646
EPS:
-2.74
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
-0.19%
1M Prestazione:
-12.52%
6M Prestazione:
-12.10%
1 anno Prestazione:
-9.30%
Intervallo 1D:
Value
$12.65
$12.91
Intervallo di 1 settimana:
Value
$11.76
$12.94
Portata 52W:
Value
$10.22
$19.62

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Nome
Pliant Therapeutics Inc
Name
Telefono
650-481-6770
Name
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Dipendente
166
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
PLRX's Discussions on Twitter

Confronta PLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
PLRX 12.72 766.15M 5.03M -185.41M -139.79M -2.74
VRTX 446.78 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.00 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.98 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.89 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.94 24.49B 3.30B -501.07M 1.03B 11.54

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-05-18 Iniziato Canaccord Genuity Buy
2023-04-13 Iniziato Robert W. Baird Outperform
2022-12-14 Iniziato Stifel Buy
2022-12-07 Iniziato JP Morgan Overweight
2022-09-01 Iniziato Citigroup Buy
2022-07-20 Iniziato SVB Leerink Outperform
2022-05-25 Iniziato Cantor Fitzgerald Overweight
2021-12-10 Iniziato Oppenheimer Outperform
2021-11-24 Iniziato RBC Capital Mkts Outperform
2021-11-03 Iniziato H.C. Wainwright Buy
2021-04-20 Iniziato BTIG Research Buy
2021-04-05 Iniziato Citigroup Buy
2020-06-29 Iniziato Citigroup Buy
2020-06-29 Iniziato Cowen Outperform
2020-06-29 Iniziato Needham Buy
2020-06-29 Iniziato Piper Sandler Overweight
Mostra tutto

Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie

pulisher
08:29 AM

Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times

08:29 AM
pulisher
08:00 AM

Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan

08:00 AM
pulisher
Nov 18, 2024

Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Objective long/short (PLRX) Report - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 11, 2024

Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK

Nov 11, 2024
pulisher
Nov 08, 2024

Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Nov 03, 2024
pulisher
Nov 03, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Nov 03, 2024
pulisher
Oct 21, 2024

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 21, 2024
pulisher
Oct 21, 2024

SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire

Oct 17, 2024
pulisher
Oct 17, 2024

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance

Oct 17, 2024
pulisher
Oct 15, 2024

Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle

Oct 14, 2024
pulisher
Oct 14, 2024

An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

How To Trade (PLRX) - Stock Traders Daily

Oct 13, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Oct 09, 2024
pulisher
Oct 07, 2024

Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance

Oct 04, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat

Oct 02, 2024
pulisher
Oct 02, 2024

Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex

Oct 02, 2024
pulisher
Oct 02, 2024

American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Oct 02, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail

Oct 01, 2024
pulisher
Oct 01, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World

Sep 30, 2024
pulisher
Sep 30, 2024

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian

Sep 30, 2024
pulisher
Sep 30, 2024

11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World

Sep 30, 2024
pulisher
Sep 28, 2024

Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa

Sep 28, 2024

Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Pliant Therapeutics Inc Azioni (PLRX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Hull Hans
Chief Business Officer
Jul 10 '24
Sale
11.56
9,900
114,444
227,494
Cummings Keith Lamont
Chief Financial Officer
Jul 10 '24
Sale
11.56
10,911
126,131
282,115
Coulie Bernard
President and CEO
Jul 10 '24
Sale
11.56
38,710
447,488
482,936
Ouimette Mike
General Counsel & Corp. Sec'y
Jul 10 '24
Sale
11.56
7,656
88,503
94,044
Cummings Keith Lamont
Chief Financial Officer
May 02 '24
Option Exercise
2.08
21,000
43,680
271,713
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '24
Sale
17.23
9,781
168,527
194,605
Hull Hans
Chief Business Officer
Jan 17 '24
Sale
17.23
9,786
168,613
185,069
Coulie Bernard
President and CEO
Jan 17 '24
Sale
17.23
25,721
443,173
316,382
Lefebvre Eric
Chief Medical Officer
Jan 17 '24
Sale
17.23
10,295
177,383
156,920
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '24
Sale
17.23
5,197
89,544
55,246
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):